ENLIVEX THERAPEUTICS ($ENLV) is expected to release its quarterly earnings data on Friday, May 23rd before market open, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.16 per share.
You can see Quiver Quantitative's $ENLV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ENLIVEX THERAPEUTICS Hedge Fund Activity
We have seen 9 institutional investors add shares of ENLIVEX THERAPEUTICS stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 426,069 shares (-19.3%) from their portfolio in Q1 2025, for an estimated $413,372
- CITADEL ADVISORS LLC added 70,136 shares (+inf%) to their portfolio in Q1 2025, for an estimated $68,045
- JANE STREET GROUP, LLC added 67,886 shares (+527.4%) to their portfolio in Q1 2025, for an estimated $65,862
- MORGAN STANLEY removed 38,970 shares (-14.5%) from their portfolio in Q1 2025, for an estimated $37,808
- MILLENNIUM MANAGEMENT LLC added 35,161 shares (+5.5%) to their portfolio in Q1 2025, for an estimated $34,113
- XTX TOPCO LTD removed 22,659 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $26,511
- RENAISSANCE TECHNOLOGIES LLC added 22,297 shares (+14.0%) to their portfolio in Q1 2025, for an estimated $21,632
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
